{"schema_version":"secwatch.filing_event.v1","accession":"0001384101-24-000116","form_type":"8-K","ticker":"VCYT","cik":"0001384101","company_name":"VERACYTE, INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.855881+00:00","generated_at":"2026-05-31T12:12:34.710484+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Veracyte Q2 revenue $114.4M (+27% YoY); net income $5.7M; record test volumes","bullets":["Total revenue $114.4M (+27% YoY); testing revenue +31%; test volume 39,023 (+23%).","Net income $5.7M; adjusted EBITDA $24.0M (21% of revenue); generated $26.7M cash.","Record Decipher Prostate volume ~19,900 (NCCN guideline boost); Afirma volume ~15,700 (new Medicare coverage for Bethesda V).","Cash and cash equivalents $235.9M; three Decipher studies published including SEER-linked analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001384101-24-000116","json":"https://secwatch.observer/filing/0001384101-24-000116.json","markdown":"https://secwatch.observer/filing/0001384101-24-000116.md","text":"https://secwatch.observer/filing/0001384101-24-000116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1384101/000138410124000116/0001384101-24-000116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1384101/000138410124000116/vcyt-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:12:34.710484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}